{
    "clinical_study": {
        "@rank": "120978", 
        "arm_group": [
            {
                "arm_group_label": "Low dose chemotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.\nCycle A\nDaily oral Thalidomide (at 3mg/kg)\nDaily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)\nDaily oral Etoposide (50 mg/m2/d) Cycle B\nDaily oral Thalidomide (at 3mg/kg)\nDaily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)\nDaily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days"
            }, 
            {
                "arm_group_label": "Best supportive care", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo: Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration)\nCapsules of same size and color as used in metronomic therapy Best supportive care\nManagement of pain as per WHO standard for pain management"
            }
        ], 
        "brief_summary": {
            "textblock": "Many of the pediatric malignancies are not curable on progression on front line or 2nd line\n      chemotherapy. Further therapy with conventional drugs imposes many side effects and\n      decreases the QOL. The usual therapy offered to such patients is best supportive care.\n\n      Metronomic chemotherapy can induce tumor stabilization or tumor responses in patients with\n      cancer that are refractory or have relapsed after conventional chemotherapy. Whether\n      metronomic therapy is better than best supportive care is not known. In order to do so, a\n      study is required which may compare metronomic therapy with a placebo therapy on PFS and QOL\n      in relapsed refractory cases of pediatric solid tumors who have failed atleast two lines of\n      chemotherapy.\n\n      HYPOTHESIS\n\n      The investigators hypothesize that metronomic chemotherapy in progressive pediatric\n      malignancy will improve PFS and QOL. If validated, then this form for therapy will be an\n      option for both the patients and the clinicians, who are left with just an option of best\n      supportive care in such situations of progressive pediatric cancers despite multiple lines\n      of chemotherapy."
        }, 
        "brief_title": "Low Dose Chemotherapy Versus Best Supportive Care in Progressive Pediatric Malignancies", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Malignant Childhood Neoplasm", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Many of the pediatric malignancies are not curable on progression on front line or 2nd line\n      chemotherapy. Further therapy with conventional drugs imposes many side effects and\n      decreases the QOL. The usual therapy offered to such patients is best supportive care.\n\n      Metronomic chemotherapy can induce tumor stabilization or tumor responses in patients with\n      cancer that are refractory or have relapsed after conventional chemotherapy. Whether\n      metronomic therapy is better than best supportive care is not known. In order to do so, a\n      study is required which may compare metronomic therapy with a placebo therapy on PFS and QOL\n      in relapsed refractory cases of pediatric solid tumors who have failed atleast two lines of\n      chemotherapy.\n\n      It will be double blind randomized study. One group will receive metronomic therapy along\n      with best supportive care and other will receive placebo and best supportive care.\n\n      The treatment will be continued till progression is documented. Metronomic chemotherapy\n      schedule : Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug\n      administration) with each drug rounded off to the nearest tablet/capsule size.\n\n      Cycle A\n\n        -  Daily oral Thalidomide (at 3mg/kg)\n\n        -  Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50\n           kg, and 400 mg BID for patients > 50 kg)\n\n        -  Daily oral Etoposide (50 mg/m2/d) Cycle B\n\n        -  Daily oral Thalidomide (at 3mg/kg)\n\n        -  Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50\n           kg, and 400 mg BID for patients > 50 kg)\n\n        -  Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days\n\n      Placebo: Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug\n      administration)\n\n        -  Capsules of same size and color as used in metronomic therapy Best supportive care\n\n        -  Management of pain as per WHO standard for pain management"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Refractory/Progressive non hematopoietic extracranial solid tumors following\n             treatment with atleast 2 lines of chemotherapy.\n\n          2. Good performance status (at least ambulatory patient)\n\n          3. Age: 5-18 years\n\n          4. Recovered from all acute toxic effects of earlier therapy\n\n          5. Absolute neutrophil count > 1X 109/L\n\n          6. Absolute platelet count > 75 x 109/L\n\n          7. Normal renal functions\n\n          8. Serum bilirubin <1.5 times the upper limit of normal, and the serum aspartate\n             aminotransferase and alanine aminotransferase < 5 times the upper limit of normal.\n\n        Exclusion Criteria:\n\n          1. Uncontrolled concurrent illness or active infection\n\n          2. Positive serology for human immunodeficiency.\n\n          3. Unable to swallow oral medication\n\n          4. Pregnant and breast-feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01858571", 
            "org_study_id": "IEC/NP-63/2013"
        }, 
        "intervention": {
            "arm_group_label": "Low dose chemotherapy", 
            "description": "Metronomic chemotherapy schedule : Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.\nCycle A\nDaily oral Thalidomide (at 3mg/kg)\nDaily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)\nDaily oral Etoposide (50 mg/m2/d) Cycle B\nDaily oral Thalidomide (at 3mg/kg)\nDaily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)\nDaily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days", 
            "intervention_name": "Low dose chemotherapy", 
            "intervention_type": "Drug", 
            "other_name": "\u2022Thalidomide \u2022Celecoxib \u2022Etoposide \u2022Cyclophosphamide"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Thalidomide", 
                "Etoposide", 
                "Celecoxib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Childhood Cancer", 
        "lastchanged_date": "May 21, 2013", 
        "location": {
            "contact": {
                "email": "sambakh@hotmail.com", 
                "last_name": "Sameer Bakhshi, MD", 
                "phone": "91-11-26588153"
            }, 
            "facility": {
                "address": {
                    "city": "New Delhi", 
                    "country": "India", 
                    "state": "Delhi", 
                    "zip": "110029"
                }, 
                "name": "All India Institute of Medical Sciences"
            }, 
            "investigator": [
                {
                    "last_name": "Sameer Bakhshi, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Atul Batra, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "2", 
        "official_title": "Low Dose Chemotherapy (Metronomic Therapy) Versus Best Supportive Care in Progressive and/or Refractory Pediatric Malignancies: a Double Blind Placebo Controlled Randomized Study", 
        "other_outcome": [
            {
                "measure": "Quality of life", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "measure": "Bio marker of angiogenesis (VEGF)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "overall_contact": {
            "email": "sambakh@hotmail.com", 
            "last_name": "Sameer Bakhshi, MD", 
            "phone": "91-11-25688153"
        }, 
        "overall_official": {
            "affiliation": "All India Institute of Medical Sciences, New Delhi", 
            "last_name": "Sameer Bakhshi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "India: Drugs Controller General of India", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01858571"
        }, 
        "responsible_party": {
            "investigator_affiliation": "All India Institute of Medical Sciences, New Delhi", 
            "investigator_full_name": "Sameer Bakhshi", 
            "investigator_title": "Additional Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Overall Survival", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 2 years"
        }, 
        "source": "All India Institute of Medical Sciences, New Delhi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "All India Institute of Medical Sciences, New Delhi", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}